Drug Approval | September 30, 2024
USFDA completes inspection at Biocon Biologics’ Insulins facility at Malaysia
The inspection concluded with the issuance of a form 483 with five observations
The inspection concluded with the issuance of a form 483 with five observations
HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
The net-zero target approval complements the company's near-term emission reduction targets
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
India has taken the lead in recognising NAFLD as a major non-communicable disease
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
The company will also share results in two additional posters for deuruxolitinib
Subscribe To Our Newsletter & Stay Updated
